Cisplatin concurrent chemoradiotherapy vs adjuvant radiation in stage IB/IIA cervical cancer with intermediate risk factors, treated with radical surgery: a retrospective study

• Published in: OncoTargets and therapy Vol. 11; pp. 1149 - 1155
• Main Authors: Sun, Hai-Yan, Tang, Qiu, Chen, Jian-Hong, Lv, Xiao-Juan, Tu, Ye-Qiang, Yan, Ding-Ding
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-01-2018; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Antineoplastic agents; Cancer patients; Cancer research; Cancer therapies; Cervical cancer; Chemoradiotherapy; Chemotherapy; Cisplatin; Comparative analysis; Health aspects; Hospitals; Hysterectomy; Medical records; Oncology; Original Research; Patients; Radiation (Physics); Radiation therapy; Radiotherapy; Risk factors; Surgery; Tumors; Women's health; intermediate risk factors; concurrent chemoradiotherapy; cervical cancer
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S158214

To determine if postoperative cisplatin concurrent chemoradiotherapy (CCRT) improves the outcome in stage IA/IIB cervical cancer patients with intermediate risk factors, when compared with radiation therapy (RT) alone, and identify the potential eligible populations for this treatment.
We reviewed medical records of 1,240 patients with stage IA/IIB cervical cancer who underwent radical hysterectomy and pelvic lymphadenectomy in our hospital between January 2008 and December 2011. Of the 1,240 patients, 436 displayed 1 or more intermediate risk factors. Of these, we screened 306 patients who underwent RT only or CCRT. We analyzed the effects of CCRT on survival and prognosis.
The 5-year progress-free survival (PFS) in the CCRT group was superior to that in the RT-only group (96.0% vs 89.0%, respectively;
=0.031). The 5-year overall survivals (OSs) were not different between the 2 groups (
=0.141). Compared with RT-only group, CCRT did not improve PFS or OS in patients with 1 risk factor, large tumor size, or deep stromal invasion (
>0.05). Compared with RT-only group, CCRT improved PFS (97.9% vs 82.8%;
=0.017) but did not increase OS (97.9% vs 89.7%;
=0.109) in patients with lymphovascular space invasion plus deep stromal invasion/large tumor size. OS (92.3% vs 70.6%;
=0.048) and PFS (92.3% vs 64.7%;
=0.020) in the CCRT group were superior to those in the RT-only group with 3 risk factors. Compared with RT-only group, CCRT was an independent prognostic factor for favorable PFS (hazard ratio [HR] =0.238; 95% CI =0.0827-0.697,
=0.009) and OS (HR =0.192; 95% CI =0.069-0.533,
=0.002).
Postoperative CCRT improved survival in stage IA/IIB cervical cancer patients with intermediate risk factors. Patients with 2 or more intermediate risk factors, including lymphovascular space invasion, may benefit from CCRT.